Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 v

Toni Choueiri, MD· @DrChoueiri · X·2026-10-25 23:48· 1 天前评分70

正文 · 原文

Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 vs 12.0 mo (HR 0.56; p=0.0005). ORR 58% vs 32%.

#ESMO26 #LungCancer @myESMO @OncoAlert

135 浏览 · 5 赞 · 2 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：Toni Choueiri, MD · x.com